09:54 AM EST - HLS Therapeutics Inc. : Announced that its New Drug Submission for PERSERIS®, a novel long-acting injectable risperidone product for the treatment of schizophrenia was accepted for review by Health Canada on January 23, 2020. HLS is seeking approval for PERSERIS with an indication for the treatment of schizophrenia in adults. HLS has in-licensed the exclusive rights to PERSERIS for the Canadian market from Indivior PLC. PERSERIS is not approved in Canada. HLS Therapeutics Inc.
shares T.HLS are trading unchanged at $23.45.
